The Promise of DARPins for Site-Specific Drug Conjugation & Pharmacokinetic Optimization
|
|
- Jodie Lynch
- 6 years ago
- Views:
Transcription
1 Department of Biochemistry The Promise of DARPins for Site-Specific Drug Conjugation & Pharmacokinetic Optimization Fabian Brandl, Plückthun Group, University of Zurich / University of Bern World ADC Berlin, 8 th -10 th February 2016
2 1. Non-IgG Binding Proteins Monoclonal Antibodies Alternative non-igg Binding Proteins Specific binding proteins Well validated Various approved human therapeutics Very successful BUT a range of restrictions Large in Size Complex multidomain structure Stability / aggregation propensity High production costs Homogeneous and site-specifically conjugated ADCs difficult to obtain Very challenging Specific binding proteins Antibody-like non-ig class proteins >50 different scaffolds proposed Numerous clinical studies ongoing Favorable properties High stability Low aggregation propensity Simple structure Low production costs (E. coli) Homogeneous and site-specific conjugates easy to obtain High freedom of engineering Facile incorporation of functional groups Compatible with non-natural amino acids Merten, H., et al. (2015). Bioconjug Chem 26(11): Plückthun, A. (2015). Annu Rev Pharmacol Toxicol 55: February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
3 2. DARPins Next Generation non-igg Binding proteins Designed Ankyrin Repeat Proteins - DARPins (one continuous protein) Very robust non-igg protein scaffold High affinity - Efficient selection of binders by Phage and Ribosome Display Immunogenicity Systemic administration found to be safe in clinical trials Methionine and Cysteine-free unique engineering possibilities for site-specific conjugation Binz et al., J Mol Bio, 2003; Binz et al., Nat Biotechnol, 2004 February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
4 3. Facile and Defined Bioconjugation Site-Specific Conjugation Chemistries Maleimide-Thiol Coupling Introduced codon: cysteine ph Very fast Click Chemistry Introduced codon: methionine Methionine Azidohomoalanine (Aha) Physiological ph slow Rate Optimized DBCO (100x faster) Aha easily incorporated by E. coli during expression Kiick, K. L., et al. (2002). Proc Natl Acad Sci USA 99(1): 19-24; Lim, R. K. and Q. Lin (2010). Chem Commun (Camb) 46(10): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
5 3. Facile and Defined Bioconjugation Click Chemistry Any position Thiol Chemistry Dye DARPin Polymer Half-life module Toxin Any position Engineering flexibility allows generation of bifunctional binders with defined stoichiometry Bifunctional binders for various applications Simon, M., et al. (2012). Bioconjug Chem 23(2): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
6 Intermediate Results DARPins are promising candidates for biomedical applications High stability, aggregation and protease resistance, ease of production, etc. Very versatile scaffold with high freedom of engineering Site-Specific and stoichiometrically defined conjugation Aim Translate advantageous properties of DARPins to therapeutic proteins Exploit site-specific conjugation for tumor targeting Drug conjugation Pharmacokinetic optimization February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
7 An Attractive Tumor Target - Epithelial Cell Adhesion Molecule (EpCAM) Tumor-associated antigen K D = 68 pm Low Levels healthy epithelia Basolateral cell surface High Levels epithelial tumors Homogeneously distributed Antibody binding has not demonstrated significant anti-tumor effects Several ADCs and Fusion-Toxins under preclinical and clinical investigation Efficient internalization on ligand binding Well suited for intracellular drug delivery Maetzel, D., et al. (2009). Nat Cell Biol 11, Simon, M. et al. (2013). Expert Opin Drug Deliv 10(4): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
8 Toxins add an effector function to EpCAM-targeting DARPins Monomethyl Auristatin F - MMAF Derivative of dolasatin-10 Synthetic antimitotic pentapeptide Microtubule destabilizing Highly potent small molecule drug IC 50 : nm on HT29 and SKBR3 Dolabella Auricularia Wedge Sea Hare Targeted MMAF is 2-3 orders of magnitude more potent February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
9 Orthogonal Assembly of a DARPin-Auristatin Bioconjugate Click Chemistry Maleimide-Thiol Chemistry Cys34 DARPin: Targeting Auristatin (MMAF): Cytotoxicity Serum Albumin: Serum Half-Life Extension Serum Albumin DBCO-PEG4-Maleimide February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
10 In vitro Performance of DARPin-Auristatin Bioconjugates for Tumor Targeting Binding Kinetics (SPR) Cytotoxicity against Various Tumor Cell Lines (XTT) Simon, M., et al. (2013). Bioconjug Chem 24(11): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
11 DARPin-Auristatin Bioconjugates for Tumor Targeting In vivo half-life In vivo efficacy AzEc1-MMAF SA-Ec1-MMAF HT29 tumor 150 mg/kg 0,2,5,8 day DARPin: 10.6 min SA-DARPin: 17.4 h Simon, M., et al. (2013). Bioconjug Chem 24(11): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
12 Pseudomonas aeruginosa exotoxin A (ETA, PE) A highly potent protein toxin NH 2 DARPin ΔIa Ia II Ib III REDLK KDEL ADPribosyltransferase Targeting EpCAM- Targeting Translocation ER localization Adapted from: Weldon, J. E. and I. Pastan (2011). FEBS J 278(23): ADP-ribosylation of the eukaryotic elongation factor 2 (eef2) Shutdown of protein synthesis Complex domain structure Targeting domain can be substituted to other targeting domains Highly potent on various cell lines (IC 50 = 5 pm) 1000x more potent than MMAF Immunogenic potential and high target-independent toxicity which limits the therapeutic window Deletion of B- and T-cell epitopes Conjugation with PEG veiling the active site February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
13 DARPin-Fusion Toxins A Very Potent Anti-Tumor Fusion Protein In vivo half-life DARPin ETA In vitro potency (IC 50 ) t ½ = 11.2 min Cell Lines Ec4-ETA Off7-ETA EpCAM + 5 fm 0.7 pm >1 nm GS-Linker EpCAM - >10 nm NA Highly potent on various EpCAM Maintain potency In vivo efficacy Pronounced anti-tumor effect with complete regression Short half-life of of 11.2 min Increase half-life Dose-limiting toxicity due to to off-target toxicity Reduce unspecific toxicity Martin-Killias, P., et al. (2011). Clin Cancer Res 17(1): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
14 A Protease-Sensitive Prodrug-Like Fusion Toxin Site specific conjugation of half-life extension / veiling module Block of active site or intracellular transport of toxin Tumor protease cleavable linker Prodrug DARPin ETA DARPin ETA Reactivation in the tumor environment What to conjugate? Where to conjugate? How to conjugate? Maintain potency Decrease unspecific toxicity Increase half-life Reduce immunogenicity Insure proper reactivation February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
15 A Protease-Sensitive Prodrug-Like Fusion Toxin 3C protease DARPin-ETA" Aha486/AhaKDEL -3C-PEG 20kDa Click kda Di-PEGylated Aha486 Click C Protease digest reactivation Free Fusion Toxin PEG 20 kda Methionine-free fusion protein Aha incorporation without loss of potency Site-specific PEG-conjugation veiling of the fusion toxin Reversible toxin inhibition Half-life extension Stefan, N., et al. (2014). Bioconjug Chem 25(12): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
16 V ia b ility (% o f u n tre a te d ) 4. Site-Specific Conjugation and Pharmacokinetic Optimization A Protease-Sensitive Prodrug-Like Fusion Toxin In vitro comparison of di-pegylated (inactivated), 3C digested (reactivated) and non-pegylated (active) fusion toxin DARPin-ETA" E486Aha+AhaKDEL -3C-PEG 20kDa Therapeutic Window Targeted PEG -PEG +PEG -PEG Non-targeted C o n c e n tra tio n (M ) Toxicity Pronounced prodrug effect with model protease 3C 1000-fold toxin inhibition Highly widened therapeutic window 6 orders of magnitude difference btw. specific and unspecific toxicity February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
17 A Protease-Sensitive Prodrug-Like Fusion Toxin Half-life increased from 7 to 80 min Active toxin Deactivated toxin Improved tolerability in vivo with increased AUC Stefan, N., et al. (2014). Bioconjug Chem 25(12): February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
18 5. Conclusions DARPins Promising non-igg binding proteins Stable and aggregation-resistant High yielding production in E. coli High freedom of engineering Facile incorporation of functional groups for site-specific and defined conjugation Site-specific and stiochiometrically defined bioconjugation allows for: Payloading of EpCAM-targeted DARPins with small molecule drugs Pharmacokinetic optimization of DARPin-Auristatin conjugates Generation of Prodrug-Like DARPin-ETA Fusion Toxins 10x improved half-life and highly improved tolerability of DARPin-ETA-PEG2 fusion toxins February 9, 2016 Fabian Brandl - University of Zurich - World ADC Berlin
19 Thank you very much for your attention! Fabian Brandl PhD student Plückthun Lab UZH The Plückies Prof. Andreas Plückthun Prof. Uwe Zangemeister-Wittke 2/15/2016 Fabian Brandl - University of Zurich - World ADC Berlin
20 Department of Biochemistry The Promise of DARPins for Site-Specific Drug Conjugation & Pharmacokinetic Optimization Fabian Brandl, Plückthun Group, University of Zurich / University of Bern World ADC Berlin, 8 th -10 th February 2016
The SMARTag TM ADC Technology Platform
The SMARTag TM ADC Technology Platform 2 3 4 World Class Protein Production Capability New State of the Art Facility Madison, WI Expanded GPEx Cell Line Engineering capacity Flexible Non cgmp production
More informationXpress CF+ : A Cell-Free Platform for the Rapid Screening and Production of Homogeneous ADCs
Xpress CF+ : A Cell-Free Platform for the Rapid Screening and Production of Homogeneous ADCs Alexander R. Steiner, M.S. Director, Protein Biochemistry Tuesday Feb 3 rd, 215 Making novel drugs is Pammolli
More informationSUPPLEMENTARY FIGURES and LEGENDS
DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency Nikolas Stefan 1, 3, Patricia Martin-Killias 1, 3, Sascha Wyss-Stoeckle 1,
More informationCreating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD
Creating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD CSO Mersana Therapeutics VC-backed Biotech in Cambridge, MA Investors: NEA, Pfizer, Fidelity,
More informationOncology Product and Platform Partnering Opportunity
Protein Medicinal Chemistry with an Expanded Genetic Code Oncology Product and Platform Partnering Opportunity April 2017 Ambrx has Made Advances in Proprietary Platform and Titer while Achieving Clinical
More informationVELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS
VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS Dr Mikael Bjerg Caspersen Industrial Biotechnology Conference August 10 th 2015 INNOVATIVE TECHNOLOGY
More informationAffimer Biotherapeutics: The preclinical development and validation of a PD-L1 antagonist in mouse
Affimer Biotherapeutics: The preclinical development and validation of a PD-L1 antagonist in mouse NGPT San Diego, 6 th June 2017 Amrik Basran Chief Scientific Officer Avacta Life Sciences Avacta Life
More informationCloudbreak: Antibody-Drug Conjugates for Treatment of MDR Gram-Negative Bacterial Infections
Cloudbreak: Antibody-Drug Conjugates for Treatment of MDR Gram-Negative Bacterial Infections James C. Levin, Ph.D. Director of Preclinical Development Discovery on Target Conference September 26, 2018
More informationTowards an in vivo Stability Assay for ADCs and Their Metabolites in Serum by Affinity Capture LC-MS
Towards an in vivo Stability Assay for ADCs and Their Metabolites in Serum by Affinity Capture LC-MS mz (@Dr_mz13), PhD 11-Feb-2013 One of the challenges of ADCs includes the development of a method to
More informationAntibody-Drug Conjugates The Road to the Current State. Nila Das, Ph.D. American Drug Delivery & Formulation Summit San Diego, CA June 13, 2016
Antibody-Drug Conjugates The Road to the Current State Nila Das, Ph.D. American Drug Delivery & Formulation Summit San Diego, CA June 13, 2016 1 Current Status of ADCs C&E News. 2014, 92(3): 13-21 2 Current
More informationImmunogenicity Assay Strategies for Antibody-Drug Conjugates
Immunogenicity Assay Strategies for Antibody-Drug Conjugates 8th World ADC Conference, San Diego 20 Sep 2017 Seema Kumar, PhD Associate Scientific Director Global Early Development (GED) EMD Serono Research
More informationThe World Leader in SPR Technology. Jimmy Page, PhD, Biacore, Inc.
The World Leader in SPR Technology Jimmy Page, PhD, Biacore, Inc. Objectives of Biacore Experiments Yes/No Data» Is there binding?» Ligand Fishing Concentration Analysis: How MUCH? Active Concentration
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW
ADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW Johannes Stanta PhD Scientific Manager, Bioanalysis EBF ADC Training day June 2017 Copyright 2017 Covance. All Rights Reserved ADC Bioanalytical PK Assays
More informationAntibody Targeted Amanitin Conjugates (ATACs) Expanding the ADC Landscape With a New Payload Targeting RNA Polymerase II
Antibody Targeted Amanitin Conjugates (ATACs) Expanding the ADC Landscape With a New Payload Targeting RNA Polymerase II ADC Summit 2016 San Diego Andreas Pahl CS Heidelberg Pharma GmbH Ladenburg, Germany
More informationDevelopment and Manufacture of a Novel Drug- Linker: Enabling High DAR ADCs. Michael J Kaufman, Ph.D. Senior Vice President, CMC
Development and Manufacture of a Novel Drug- Linker: Enabling High DAR ADCs Michael J Kaufman, Ph.D. Senior Vice President, CMC Legal Disclaimer This presentation contains forward-looking statements that
More informationLinker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.
Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials Introduction p. 1 Roles of Regulatory Scientists p. 2 Product Development and Availability p. 2 Data Requirements
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-16-1-0595 TITLE: Prostate-Specific Membrane Antigen (PSMA) Targeted Bio-orthogonal Therapy for Metastatic Prostate Cancer PRINCIPAL INVESTIGATOR: Dmitri Artemov., Ph.D. CONTRACTING
More informationAntibody-Drug Conjugate Bioanalytical Assay Development:
Antibody-Drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenges November 16, 2016 Presented by Corinna Fiorotti, Ph.D. Presentation Overview ADC Overview ADC Assays ADC Immunogenicity
More informationAntibody-Drug Conjugate Characterization and Quality Assurance
Antibody-Drug Conjugate Characterization and Quality Assurance Sarah Kennett Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA October 12, 2011 1 Disclaimer The views and
More informationPreclinical to Clinical Translation of Antibody Drug Conjugates
Preclinical to Clinical Translation of Antibody Drug Conjugates Robert Lutz, PhD Crescendo Biopharma Consulting World ADC Summit Berlin 2016 1 Bio ImmunoGen 23 years Researcher in cell death and survival
More informationInvestigations in Immune Suppression for Monoclonal Antibody Therapeutics
Investigations in Immune Suppression for Monoclonal Antibody Therapeutics Vibha Jawa Principal Scientist AAPS NBC Meeting, May 2016 Clinical Immunology, Medical Sciences, Amgen Background Therapeutic proteins
More informationChallenges in Bioassay Development for ADCs and Their Utility for Measuring In-vitro Activity of Conjugate Variants
Challenges in Bioassay Development for ADCs and Their Utility for Measuring In-vitro Activity of Conjugate Variants Sonia Connaughton, Ph.D. Senior Scientist, Bioanalytical Science Bioassays 214: Scientific
More informationBEH.462/3.962J Molecular Principles of Biomaterials Spring 2003
Lecture 17: Drug targeting Last time: Today: Intracellular drug delivery Drug targeting Reading: T.J. Wickham, Ligand-directed targeting of genes to the site of disease, Nat. Med. 9(1) 135-139 (2003) Drug
More informationA New Peptide Drug Modality; Helix-Loop-Helix Technology. Interprotein Corporation
A New Peptide Drug Modality; Helix-Loop-Helix Technology Interprotein Corporation 1 Interprotein Corporation Location: Osaka, Japan Year Established: 2001 CEO & President: Masato Hosoda www.interprotein.com
More informationWorkshop F: Linker Design: Why so complex?
Genomics Institute of the Novartis Research Foundation Workshop F: Linker Design: Why so complex? Bernhard Geierstanger October 10, 2016 Antibody Drug Conjugates Novel targets & Biology Diverse set of
More informationWhat is an Aptamer? smallest unit of repeating structure
What is an Aptamer? apto: mer: to fit smallest unit of repeating structure Aptamers are single stranded folded oligonucleotides that bind to molecular (protein) targets with high affinity and specificity
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationFc engineering for improved developability and retained biological activity
Fc engineering for improved developability and retained biological activity M. Jack Borrok Antibody Discovery & Protein Engineering Department Medimmune, Gaithersburg MD, USA Knect 365 Antibody Engineering
More informationExpert Consensus on Quality Control and Preclinical Evaluation of Antibody-Drug Conjugates
Expert Consensus on Quality Control and Preclinical Evaluation of Antibody-Drug Conjugates National Institutes for Food and Drug Control July 20 th, 2018 Contents 1. Overview... 3 2. Manufacturing... 4
More informationOrthogonal Assembly of a Designed Ankyrin Repeat Protein Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension
pubs.acs.org/bc Orthogonal Assembly of a Designed Ankyrin Repeat Protein Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension Manuel Simon,, Raphael Frey, Uwe Zangemeister-Wittke,*,,
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More informationOverview of the Antibody Drug Conjugate Landscape Godfrey Amphlett WCBP CMC Strategy Forum January 24, 2010
Overview of the Antibody Drug Conjugate Landscape Godfrey Amphlett WCBP CMC Strategy Forum January 24, 2010 Outline of Talk What is an Antibody Drug Conjugate (ADC)? Rationale for developing ADC s What
More informationphab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis Promega Corporation
phab Amine and Thiol Reactive Dyes for Antibody Internalization Studies Nidhi Nath, Ph.D. Group Leader, Protein Analysis 1 Outline 1. phab Dyes 2. Protocols for conjugating phab Dyes to antibodies 3. Applications:
More informationMolecular basis of Valine-Citrulline-PABC linker instability in site-specific ADCs & its mitigation by linker design
Molecular basis of Valine-Citrulline-PABC linker instability in site-specific ADCs & its mitigation by linker design Magdalena Dorywalska, Ph.D. Rinat, ORD, Pfizer World ADC San Diego 2016 ADCs require
More informationFDA Draft Guidance on Immunogenicity Testing
FDA Draft Guidance on Immunogenicity Testing Susan Kirshner, Ph.D. Associate Chief, Laboratory of Immunology Division of Therapeutic Proteins OBP/CDER/FDA EBF 2010 Guidance for Industry Assay Development
More informationAbGn-107, an ADC Targets Gastrointestinal Tumors
AbGn-107, an ADC Targets Gastrointestinal Tumors For a Healthier Life Presented by Ron Lin Feb. 22, 2016 All Rights reserved AbGenomics International Inc. 4966 El Camino Real, Suite 200, Los Altos, CA
More informationUnique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd
Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations [mabs -monoclonal antibodies ] Peter Lloyd Head of Pharmacokinetics-Pharmacodynamics Novartis Biologics
More informationANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES
ANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES Brian DiPaolo 08 June 2017 CASSS Midwest Discussion Group Agenda Introduction Antibody Drug Conjugates
More informationDiscovery on Target. Short Course Preview Deck
Discovery on Target Short Course Preview Deck Targeting of GPCRs with Monoclonal Antibodies Barbara Swanson, Ph.D. Sorrento Therapeutics, Inc. October 2014 GPCR Short Course Overview Introductions Brief
More informationHong Kong Pharmacy Conference Feb 2017 WHAT S IN A NAME NOMENCLATURE OF MONOCLONAL ANTIBODIES
Hong Kong Pharmacy Conference Feb 2017 WHAT S IN A NAME NOMENCLATURE OF MONOCLONAL ANTIBODIES Things you get after 20 mins: 1. How drugs are named 2. Monoclonal antibodies (mab) as an example: A. How to
More informationflexible by design ProTIA Bispecific T cell engagers designed for local activation in the tumor environment
flexible by design ProTIA Bispecific T cell engagers designed for local activation in the tumor environment Volker Schellenberger, PhD Keynote lecture at 4 th Biologics Congress, Berlin 2018 1 Cancer Therapeutics
More informationDDI Assessment for Therapeutic Proteins and ADCs
DDI Assessment for Therapeutic Proteins and ADCs Elimika Pfuma Fletcher, PharmD, PhD Policy Lead Guidance and Policy Team Office of Clinical Pharmacology CDER/FDA 06/21/2017 DDI- 2017 International Conference
More informationGE Healthcare Life Sciences. A year of interaction with Biacore X100
GE Healthcare Life Sciences A year of interaction with Biacore X1 Protein interaction research Real-time monitoring of binding events using surface plasmon resonance (SPR) gives a deep understanding of
More informationTowards Single Molecule Detection of SEB A Mobile Sandwich Immunoassay on Gliding Microtubules. Dr. Carissa M. Soto
Towards Single Molecule Detection of SEB A Mobile Sandwich Immunoassay on Gliding Microtubules Dr. Carissa M. Soto March 8, 2008 Dr. Kim E. Sapsford, Dr. Brett D. Martin, Dr. Amy Szuchmacher Blum, and
More informationControl Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design!
Control Strategies for Antibody-based Immuno-oncology Products: It Starts with Product Design! Marjorie Shapiro Office of Biotechnology Products/FDA WCBP 2017 January 25, 2017 Disclaimer The views presented
More informationADME and DDI Potential of Antibody-Drug Conjugates. Nagendra V. Chemuturi, Ph.D DDI, Seattle, WA
ADME and DDI Potential of Antibody-Drug Conjugates Nagendra V. Chemuturi, Ph.D. 2016 DDI, Seattle, WA Today s Presentation What are Antibody-Drug Conjugates (ADCs)? ADC technology ADME of ADCs Typical
More informationB-cell Epitope Prediction and Cloning monoclonal ADAs
B-cell Epitope Prediction and Cloning monoclonal ADAs Stefan Ryser, CEO, Trellis Bioscience 3 rd International Symposium on Higher Order Structure of Protein Therapeutics Arlington, Virginia, February
More informationAlternate Approaches Addressing Variability in ADCC Assay. Prabhavathy Munagala, Ph.D. United States Pharmacopeia, India October 28, 2014
Alternate Approaches Addressing Variability in ADCC Assay Prabhavathy Munagala, Ph.D. United States Pharmacopeia, India October 28, 2014 Disclaimer It is a scientific presentation and Conclusions presented
More informationEnhance Your Protein Interaction Research with A New Level of Bench-Top Productivity
LAMDAGEN C O R P O R A T I O N Enhance your research with real-time monitoring and quantitation of biomolecular binding with highly sensitive detection in a label-free format 9 Enhance Your Protein Interaction
More informationPhage Antibody Selection With Reichert SPR System
Phage Antibody Selection With Reichert SPR System Reichert Technologies Webinar April 4, 2016 Mark A. Sullivan, Ph.D. Department of Microbiology and Immunology University of Rochester Presentation Outline
More informationChemical Peptide Synthesis in the Development of Protein Therapeutics
Chemical Peptide Synthesis in the Development of Protein Therapeutics Stephen Kent Abstract Effective automated SPPS is key to the synthesis of peptide building blocks for chemical protein synthesis, and
More informationINNOVATIVE DEVELOPMENT STRATEGIES AND APPLICATIONS FOR BISPECIFIC ANTIBODIES
INNOVATIVE DEVELOPMENT STRATEGIES AND APPLICATIONS FOR BISPECIFIC ANTIBODIES Advanced protein design and engineering techniques have enabled the production of bispecific antibodies, unique antibody constructs
More informationPartnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION DECEMBER 2016
Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION DECEMBER 2016 Corporate Overview A unique source of therapeutic human antibodies with one of the industry's most versatile
More informationIntra-tumor Catabolites (fate of ADC) can Predict ADC Efficacy. Donglu Zhang, Ph.D. Genentech Feb 21, 2017 World ADC Berlin-2017
Intra-tumor Catabolites (fate of ADC) can Predict ADC Efficacy Donglu Zhang, Ph.D. Genentech Feb 21, 2017 World ADC Berlin-2017 1 Outline ADC structure and mechanism of action (MOA) Can we use PK or PK-PD
More informationModule 2 overview SPRING BREAK
1 Module 2 overview lecture lab 1. Introduction to the module 1. Start-up protein eng. 2. Rational protein design 2. Site-directed mutagenesis 3. Fluorescence and sensors 3. DNA amplification 4. Protein
More informationGenmab an antibody innovation powerhouse. Jan van de Winkel
Genmab an antibody innovation powerhouse Jan van de Winkel Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationImmunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN
Immunodiscovery developing antibodies for research, diagnosis and therapy MATS OHLIN Immunotechnology a department at Lund University exploiting advanced technologies in biomedicine Genomics Antibody technology
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationAffinity Reagents: The Landscape and Affimer Technology Competitive Advantages
Affinity Reagents: The Landscape and Affimer Technology Competitive Advantages Introduction It is well accepted that the limitations of antibodies present valuable commercial opportunities for alternative
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationSite-Specific ADC Generation Using SMARTag Technology
Site-Specific ADC Generation Using SMARTag Technology David Rabuka, PhD World ADC Summit San Diego, Oct 2015 SMARTag TM technology: Site-specific protein modification using bioorthogonal chemistry Site-Specific
More informationOX40 MARKET LANDSCAPE
OX40 Agonist OX40 MARKET LANDSCAPE OX40 (a.k.a. CD134) is a costimulatory molecule belonging to the TNF receptor family expressed primarily on activated effector T (T eff) cells and naive regulatory T
More informationApproaches to Nanoparticle Targeting. Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology
Approaches to Nanoparticle Targeting Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology Principles of drug targeting Drug targeting is the systemic or local administration
More informationMolecules and Particles as Nano- and Micro-scale Drug Carriers
Molecules and Particles as Nano- and Micro-scale Drug Carriers Last time: molecular switches Molecular railways Proteins as motors in nanodevices Today: nano- and micro-particle drug carriers Reading:
More informationPartnered Discovery of High-quality Antibody Drug Candidates
Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION SEPTEMBER 2017 Corporate Overview A unique source of therapeutic human antibodies with one of the industry's most versatile
More informationPolypharmacology. Giulio Rastelli Molecular Modelling and Drug Design Lab
Polypharmacology Giulio Rastelli Molecular Modelling and Drug Design Lab www.mmddlab.unimore.it Dipartimento di Scienze della Vita Università di Modena e Reggio Emilia giulio.rastelli@unimore.it Magic
More informationTargeting Proteins for Degradation: Characterizing PROTAC Kinetics and Mode of Action using Live-Cell Assays. Kristin M. Riching, Ph.
Targeting Proteins for Degradation: Characterizing PROTAC Kinetics and Mode of Action using Live-Cell Assays Kristin M. Riching, Ph.D PROTACs: An Attractive Drug Discovery Strategy PROTACs, or Proteolysis
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationMore choices, better detection.
3 Protein Detection More choices, better detection. Perform Western blotting experiments faster and easier with our new Thermo Scientific Pierce G2 Fast Blotter and accessories, and push your microscopy
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationMonitoring Charge Heterogeneity of Antibody-Maytansinoid Conjugates (AMC) with icief
Monitoring Charge Heterogeneity of Antibody-Maytansinoid Conjugates (AMC) with icief Joyce Lin, Rajesh Krishnamurthy, Alexandru Lazar ImmunoGen, Inc., Waltham, MA CE Pharm 2008 utline I. Introduction of
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationInterplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology
Interplay of Cells involved in Therapeutic Agent Immunogenicity Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology Disclosure The author works with Amicus on an immunogenicity project
More informationRapid Development and Manufacture of ADC's- Integration of Antibody and ADC Process Development and Optimisation"
Rapid Development and Manufacture of ADC's- Integration of Antibody and ADC Process Development and Optimisation" Bo Kara, Director Science and Technology Fujifilm Diosynth Biotechnologies, UK Biomanufacturing
More informationThermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis
Thermo Scientific MAbPac HIC Columns Novel Hydrophobic Interaction HPLC Columns Designed for Monoclonal Antibody Analysis Introduction The Thermo Scientific MAbPac HIC column family is designed for separations
More informationANTIBODY IMMUNOGENICITY
ANTIBODY IMMUNOGENICITY Tolerance Classical Immunity To aggegated Antibody Chiller and Weigle, PNAS, 65:551, 1970; Benjamin and Waldmann, et al, J Exp Med, 163:1539, 1986) THE IMMUNOGENICITY PROBLEM WITH
More informationAdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis
Application Note Biologics Development AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis Using the Agilent 16 Infinity II Bio-Inert LC Authors Andrew Coffey and Sandeep
More informationPhage selection of bicyclic peptides to challenging protein targets
Advances in protein-protein interaction analysis and modulation Phage selection of bicyclic peptides to challenging protein targets Christian Heinis, Assistant Professor EPFL, Lausanne, Switzerland EMBO
More information6 th EBF Open meeting, Barcelona November 21st, 2013
Validation of an immunoassay to selectively quantify the naked antibody of a new Sanofi Antibody Drug Conjugate: an additional tool for improvement of PK interpretation 6 th EBF Open meeting, Barcelona
More informationStrategy for Selecting NAb Assay Format
Strategy for Selecting NAb Assay Format European Bioanalysis Forum 27Sept2016 Jim McNally, Ph.D. Associate Director, Global Early Development Head of Clinical Bioanalytics Merck KGaA AAPS Working Group
More informationAddressing challenges of targeting the macrophage checkpoint, CD47. Marie Kosco-Vilbois, PhD CSO
Addressing challenges of targeting the macrophage checkpoint, CD47 Marie Kosco-Vilbois, PhD CSO 1 CD47 is an immune checkpoint Cancer cell Macrophage Activating eat me signal CD47 Inhibitory don t eat
More information! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationPartnered Discovery of High-Quality Antibody Drug Candidates. Company Presentation
Partnered Discovery of High-Quality Antibody Drug Candidates Company Presentation AbCheck s Unique Offering A unique source of human antibodies with one of the industry's most versatile technology platforms
More informationIdentification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3*
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 270, No. 40, Issue of October 6, pp. 23373 23380, 1995 Printed in U.S.A. Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies
More informationModule 2 overview SPRING BREAK
1 Module 2 overview lecture lab 1. Introduction to the module 1. Start-up protein eng. 2. Rational protein design 2. Site-directed mutagenesis 3. Fluorescence and sensors 3. DNA amplification 4. Protein
More informationImmunogenicity. How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit
Immunogenicity How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit Club Phase I, 22 March 2016 1 Outline Introduction to immunogenicity Analytical challenges for immunogenicity
More informationRecombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016
Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production
More informationPLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS
PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS Louise Angell Lead Scientist 10th Biosimilars & Follow-On Biologics Congregation 9 th May 2017 Copyright @ 2017 Covance. All rights Reserved Overview
More informationMatthias Grossmann, MD PhD Principal Consultant Early Phase 2013 PAREXEL International
Challenges in translating a candidate antibody to clinical development Matthias Grossmann, MD PhD Principal Consultant Early Phase 2013 PAREXEL International Agenda Early clinical development of therapeutic
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationAdvanced Therapeutic Antibody Discovery with Multiplexed Screening
Advanced Therapeutic Antibody Discovery with Multiplexed Screening White Paper Scientists need powerful tools that can deliver results to fully understand the ability of candidate antibodies to interrupt
More informationRECRUIT-TandAbs: a versatile bispecific antibody platform designed for immune therapy of cancer. Eugene Zhukovsky
RECRUIT-TandAbs: a versatile bispecific antibody platform designed for immune therapy of cancer Eugene Zhukovsky 29th Monoclonal Antibodies Meeting, Mykonos 2012 Affimed s profile Affimed is a clinical
More informationNeutralising Assay Methodologies
Neutralising Assay Methodologies March 9 th, 2016 EMA workshop on immunogenicity assessment of biotechnology derived therapeutic proteins Shalini Gupta, PhD Amgen Inc. shalinig@amgen.com 1 Key Points About
More informationApplied Protein Services
Applied Protein Services Applied Protein Services A Window into the Future Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical pipeline. To help
More informationStrategic Collaboration with Amgen to develop MP0310
Strategic Collaboration with Amgen to develop MP0310 Patrick Amstutz, CEO Webcast of Molecular Partners AG, Switzerland (SIX: MOLN) December 19, 2018 2018 Molecular Partners AG Slide 1 Molecular Partners:
More information